Differential effect of oral dehydroepiandrosterone-sulphate on metabolic syndrome features in pre- and postmenopausal obese women

Clinical Endocrinology

Volumn 77, Issue 4, 2012, Pages 548-554

  Gómez Santos, Cecilia ^a   Hernández Morante, Juan José ^a,b   Tébar, Francisco Javier ^c   Granero, Esteban ^d   Garaulet, Marta ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b CATHOLIC UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d Health Service   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRASTERONE SULFATE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTITUTION THERAPY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; DEHYDROEPIANDROSTERONE SULFATE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PREMENOPAUSE;

EID: 84867292555     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04306.x     Document Type: Article

References (38)

1. Sone, H., Tanaka, S., Iimuro, S. et al. (2009) Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS). Journal of Atherosclerosis and Thrombos 16, 380-387.
2. Church, T.S., Thompson, A.M., Katzmarzyk, P.T. et al. (2009) Metabolic syndrome and diabetes, alone and in combination, as predictors of cardiovascular disease mortality among men. Diabetes Care 32, 1289-1294.
3. Florentin, M., Elisaf, M.S., Mikhailidis, D.P. et al. (2009) Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. Current Pharmaceutical Design 15, 3446-3462.
4. Denke, M.A. & Pasternak, R.C. (2001) Defining and treating the metabolic syndrome: a primer from the Adult Treatment Panel III. Current Treatment Options in Cardiovascular Medicine 3, 251-253.
5. Alberti, K.G., Zimmet, P. & Shaw, J. (2005) IDF Epidemiology Task Force Consensus Group: the metabolic syndrome-a new worldwide definition. Lancet 366, 1059-1062.
6. Garaulet, M., Perez-Llamas, F., Fuente, T. et al. (2000) Anthropometric, computed tomography and fat-cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. European Journal of Endocrinology 143, 657-666.
7. Couillard, C., Gagnon, J., Bergeron, J. et al. (2000) Contribution of body fatness and AT distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE family study. Journal of Clinical Endocrinology and Metabolism 85, 1026-1031.
8. Dhatariya, K., Bigelow, M.L. & Nair, K.S. (2005) Effect of dehydroepiandrosterone replacement on insulin sensitive & lipids in hypoadrenal women. Diabetes 54, 765-769.
9. Flynn, M.A., Weaver-Osterholtz, D., Sharpe- Timms, K.L. et al. (1999) Dehydroepiandrosterone replacement in aging humans. Journal of Clinical Endocrinology and Metabolism, 84, 4748-4749.
10. Villareal, D.T. & Holloszy, J.O. (2004) Effect of DHEA on Fat, Abdominal & Action, Insulin in Women, Elderly & Men. JAMA, 292, 2243-2248.
11. Lasco, A., Frisina, N., Morabito, N. et al. (2001) Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology, 145, 457-461.
12. Jedrzejuk, D., Medras, M., Milewicz, A. et al. (2003) Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male, 6, 151-156.
13. Nestler, J.E., Barlascini, C.O., Clore, J.N. et al. (1988) Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. Journal of Clinical Endocrinology and Metabolism 66, 57-61.
14. Sánchez, J., Pérez-Heredia, F., Priego, T. et al. (2008) Dehydroepiandrosterone prevents age-associated alterations, increasing insulin sensitivity. Journal of Nutritional Biochemistry 19, 809-818.
15. Hernández-Morante, J.J., Pérez-de-Heredia, F., Luján, J.A. et al. (2008) Role of DHEA-S on body fat distribution: gender- and depotspecific stimulation of adipose tissue lipolysis. Steroids 73, 209-215.
16. Sader, S., Nian, M. & Liu, P. (2003) Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation 108, 644-646.
17. Katsuki, A., Urakawa, H., Gabazza, E.C. et al. (2004) Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. European Journal of Endocrinology 151, 573-577.
18. Hernandez- Morante, J.J., Milagro, F., Gabaldon, J.A. et al. (2006) Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. European Journal of Endocrinology 155, 593-600.
19. Pérez-de-Heredia, F., Sánchez, J., Priego, T. et al. (2008) Adiponectin is involved in the protective effect of DHEA against metabolic risk in aged rats. Steroids 73, 1128-1136.
20. Tchernof, A., Poehlman, E.T. & Despres, J.P. (2000) Body fat distribution, the menopause transition, and hormone replacement therapy. Journal of Diabetes and Metabolism 26, 12-20.
21. Salas-Salvadó, J., Rubio, M.A., Barbany, M. et al. (2007) SEEDO 2007 Consensus for the evaluation of overweight and obesity and the establishment of therapeutic intervention criteria. Medicina Clínica 128, 184-196.
22. Ritchie, J.D., Miller, C.K. & Smiciklas-Wright, H. (2005) Tanita foot-to-foot bioelectrical impedance analysis system validated in older adults. Journal of the American Dietetic Association 105, 1617-1619.
23. Ruano, M., Silvestre, V., Castro, R. et al. (2006) HOMA, QUICKI and MFfm to measure insulin resistance in morbid obesity. Obesity Surgery 16, 549-553.
24. Ascaso, J.F., Romero, P., Real, J.T. et al. (2001) Insulin resistance quantification by fasting insulin plasma values and HOMA indexing a non-diabetic population (article in Spanish). Medicina Clinica (Barc) 117, 530-533.
25. Tagliaferro, A.R., Ronan, A.M., Payne, J. et al. (1995) Increased lipolysis to b-adrenergic stimulation after dehydroepiandrosterone treatment in rats. American Journal of Physiology (Regulatory Integrative Comp Physiol 37), 268, R1374-R1380.
26. Mortola, J.F. & Yen, S.S. (1990) The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 71, 696-704.
27. Maccario, M., Mazza, E., Ramunni, J. et al. (1999) Relationships between dehydroepiandrosterone-sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women. Clinical Endocrinology (Oxford), 50, 595-600.
28. Pérez-de Heredia, F., Hernández-Morante, J.J. & Garaulet, M. (2011). Adipose Tissue as a Target for Dehydroepiandrosterone and its Sulphate. DHEA in Human Health and Aging.
29. Casson, P.R., Toth, M.J., Johnson, J.V. et al. (2010) Correlation of serum androgens with anthropometric and metabolic indices in healthy, nonobese postmenopausal women. Journal of Clinical Endocrinology and Metabolism 95, 4276-4282.
30. Villareal, D.T., Holloszy, J.O. & Kohrt, W.M. (2000) Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clinical Endocrinology 53, 561-568.
31. Yang, S.C., Chen, C.Y., Liao, Y.H. et al. (2005) Interactive effect of an acute bout of resistance exercise and dehydroepiandrosterone administration on glucose tolerance and serum lipids in middleaged women. Chinese Journal of Physiology 48, 23-29.
32. Power, M. & Pratley, R. (2011) Alternative and complementary treatments for metabolic syndrome. Current Diabetes Reports 11, 173-178.
33. Oliver, T., Wolf, A., Birthe Köster, B. et al. (1997) A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels. Biological Psychiatry 42, 845-848.
34. Phillips, A.C., Carroll, D., Gale, C.R. et al. (2010) Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study.. European Journal of Endocrinology 162, 919-923.
35. Apostolova, G., Schweizer, R.A., Balazs, Z. et al. (2005) Dehydroepiandrosterone inhibit the amplification of glucocorticoid action in adipose tissue. American Journal of Physiology. Endocrinology and Metabolism 288, E957-E964.
36. Davis, S.R., Panjari, M. & Stanczyk, F.Z. (2011) Clinical review: DHEA replacement for postmenopausal women. Journal of Clinical Endocrinology and Metabolism 96, 1642-1653.
37. Fogle, R.H., Stanczyk, F.Z., Zhang, X. et al. (2007) Ovarian androgen production in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 92, 3040-3043.
38. Gambineri, A., Forlani, G., Munarini, A. et al. (2009) Increased clearance of cortisol by 5 beta- reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. Journal of Endocrinological Investigation 32, 210-218.